Top Markets
Coin of the day
Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.

ZYNE
Rang in Aktien #26763
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in... Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Aktienkurs
$1.30
Zuletzt synchronisiert: 2023-10-13
Marktkapitalisierung
$38.02M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Zynerba Pharmaceuticals, Inc. (ZYNE)

Kategorie

Kursverlauf für Zynerba Pharmaceuticals, Inc. (ZYNE)
Höchster Schlusskurs: $1.27 am 2023-10-01

Niedrigster Schlusskurs: $28.18 am 2015-08-01
Kursverlauf der Aktie von Zynerba Pharmaceuticals, Inc. von 2015 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 121.20%
2022 -82.15%
2021 -16.92%
2020 -34.43%
2019 51.25%
2018 -67.91%
2017 -17.16%
2016 20.03%
2015 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$171.67 -
DE
$163.21 25.45%
DE
$38.00 22.72%
JP
$220.18 33.00%
CH
$21.01 11.96%
IN